title: [Response rates following neoadjuvant chemotherapy and breast preserving treatment in patients with locally advanced breast cancer].
abstract: BACKGROUND
  The neoadjuvant chemotherapy is increasingly being used in the treatment of patients with locally advanced breast cancer. We describe the hypothesis of the biological behaviour of breast cancer supporting the reason for the existence of this treatment. The improvement of neoadjuvant chemotherapy is being discussed as well as the advantages, disadvantages and problems of the treatment. THE AIM OF EXAMINATION: To study the results of neoadjuvant chemotherapy in patients with locally advanced breast cancer and the proportion of breast preserving surgery after the treatment.
  
  
  METHODS
  Sixty seven patients were given neoadjuvant chemotherapy treatment between 01.01.1999 and 12.31.2003. Twenty three patients were stage III A while 35 stage III B and 9 stage III C. 63% of the patients received CEF chemotherapy and 19% were given MMM. 18% were given neoadjuvant Taxotere + Carboplatin and 4% were given Taxotere + Farmorubicin chemotherapy.
  
  
  RESULTS
  After neoadjuvant chemotherapy 5 patients had SD (stable disease), 32 patients had MR (minor response) and in 28 cases patients had PR (partial response). Two patients showed pCR (complete pathologic response). Twenty patients (30%) had breast preserving surgery.
  
  
  CONCLUSIONS
  On the basis of our own experience neoadjuvant therapy is justified in patients with locally advanced breast cancer as they have bigger chance for breast preserving surgery. If mastectomy and axillary block dissection has to be carried out they are easier to perform. Taxans must be introduced for neoadjuvant treatment in order to improve our results. A longer follow-up is necessary before drawing final conclusions.
authors.affiliation: Bács-Kiskun Megyei Onkormányzat Kórháza Kecskemét. marazr@freemail.hu
authors.forename: Róbert
authors.initials: R
authors.lastname: Maráz
authors.forename: Gábor
authors.initials: G
authors.lastname: Boross
authors.forename: Mihály
authors.initials: M
authors.lastname: Svébis
authors.forename: Rita
authors.initials: R
authors.lastname: Gyánti
authors.forename: Rita
authors.initials: R
authors.lastname: Vizhányó
authors.forename: Lajos
authors.initials: L
authors.lastname: Hajnal
authors.forename: László
authors.initials: L
authors.lastname: Markó
authors.forename: Miklós
authors.initials: M
authors.lastname: Szucs
authors.forename: Eva
authors.initials: E
authors.lastname: Ambrózay
authors.forename: Margit
authors.initials: M
authors.lastname: Lorincz
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery / Q000628:therapy*; D016190:Carboplatin / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D000077143:Docetaxel; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015412:Mastectomy, Segmental; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods; D009367:Neoplasm Staging; D012189:Retrospective Studies; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D043823:Taxoids; D003561:Cytarabine; D000077143:Docetaxel; D015251:Epirubicin; D003520:Cyclophosphamide; D016190:Carboplatin